Core Viewpoint - MetaVia Inc. has announced a private placement expected to generate approximately $10.0 million in gross proceeds, aimed at supporting the clinical development of its obesity treatment, DA-1726 [1][2]. Group 1: Private Placement Details - The offering includes the purchase of 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded warrants at $0.709 each, with an exercise price of $0.001 [2]. - The private placement is priced at-the-market under Nasdaq rules, with the closing expected around May 12, 2025, subject to customary conditions [2]. Group 2: Regulatory and Compliance Information - The securities are being offered to certain institutional accredited investors and are not registered under the Securities Act, thus cannot be sold in the U.S. without an effective registration statement or applicable exemption [3]. - MetaVia plans to file a registration statement with the SEC for the resale of the shares issued in the private placement and to obtain stockholder approval for the underlying shares of the pre-funded warrants [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [5]. - DA-1726 is a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, potentially leading to superior weight loss compared to selective GLP1R agonists [5]. - DA-1241 is a GPR119 agonist that promotes the release of gut peptides and has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [5].

Group 1 - KWESST Micro Systems Inc. has regained compliance with Nasdaq's minimum bid price requirement after achieving a closing bid price of at least USD$1.00 per common share for 10 consecutive business days from April 24, 2025, to May 7, 2025 [1][2] - The listing matter regarding the company's compliance has been closed, allowing its common shares and public warrants to continue trading on Nasdaq under the symbols "KWE" and "KWESW" respectively [2] Group 2 - KWESST develops and commercializes next-generation tactical systems for military and security forces, focusing on digitization for real-time situational awareness and targeting information [3] - The company's product offerings include countermeasures against electronic detection, lasers, and drones, which can operate independently or integrate with existing systems [3] - KWESST also has a proprietary non-lethal product line branded PARA OPSTM, applicable across various segments including law enforcement [3]

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

In October of 2024, mega asset manager BlackRock introduced three very interesting ETFs, of which two were intended to capture the momentum and performance of the top 20 and top 30 of Nasdaq-100 stocks, respectively, while the third was intended Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alph ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1]. - The content may include advertisements and promotional materials, with the website potentially receiving compensation from third parties [1].

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for April 2025 on its Investor Relations website. A data sheet showing this information can be found at: http://ir.nasdaq.com/financials/volume-statistics. About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We ...

Company Overview - Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients without the systemic side effects associated with current treatments [4]. Stock Option Grant - On May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to a new employee under its 2022 Inducement Stock Incentive Plan [1]. - The exercise price for the stock options is set at $0.755 per share, which matches the closing price of the company's common stock on the grant date [2]. - The stock options have a ten-year term, with 25% of the shares vesting on the first anniversary of employment and the remaining 75% vesting in 36 equal monthly installments, contingent on continued service with the company [2][3]. Compliance and Inducement - The stock options are granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the individual entering employment with the company [3].

Core Points - Adverum Biotechnologies granted inducement awards to seven new employees, including non-qualified stock options for 32,620 shares and restricted stock units (RSUs) for 16,310 shares under its 2017 Inducement Plan [1][2] - The stock options have an exercise price of $3.33 per share, equal to the closing price on the grant date, and vest over four years [2] - The RSUs vest over three years, with one-third vesting on each anniversary of the applicable vesting commencement date [2] Company Overview - Adverum Biotechnologies is a clinical-stage company focused on gene therapy to preserve sight in prevalent ocular diseases, aiming to develop functional cures to restore vision and prevent blindness [3] - The company utilizes its proprietary intravitreal (IVT) platform to create durable, single-administration therapies, reducing the need for frequent ocular injections [3] - Adverum is evaluating its gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), as a one-time IVT injection for patients with neovascular or wet age-related macular degeneration [3]

Market Performance - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 300 points on Friday. The Dow rose by 1.43% to 41,337.37, the NASDAQ climbed 1.76% to 18,023.33, and the S&P 500 gained 1.61% to 5,694.47 [1] - In the commodities market, oil prices decreased by 1.5% to $58.38, while gold prices increased by 0.4% to $3,234.20. Silver fell by 1% to $32.150, and copper rose by 1.2% to $4.6825 [5] Company Earnings - Apple Inc. reported a fiscal second-quarter revenue of $95.36 billion, surpassing analyst expectations of $94.53 billion. The earnings per share were $1.65, exceeding the forecast of $1.63. However, shares fell approximately 4% following the announcement [2] Sector Performance - Communication services stocks saw a significant increase of 2.7% on Friday, while consumer staples stocks rose modestly by 0.6% [1] Notable Stock Movements - Polyrizon Ltd. shares surged by 295% to $1.0002 after a successful safety study of its allergy blocker formulation [7] - Freight Technologies, Inc. shares increased by 111% to $2.0808 following an agreement for the issuance of convertible notes worth up to $20 million [7] - Adaptive Biotechnologies Corporation shares rose by 36% to $10.02 after beating EPS and revenue estimates in its first-quarter results [7] - Pineapple Financial Inc. shares dropped by 34% to $0.1289 after announcing a $1.5 million public offering [7] - Cable One, Inc. shares fell by 42% to $152.23 after reporting disappointing first-quarter results and receiving a downgrade from Keybanc [7] - Draganfly Inc. shares decreased by 35% to $1.9050 after pricing a $3.6 million public offering at $2.10 per unit [7] International Markets - European shares showed positive performance, with the eurozone's STOXX 600 gaining 1.67%, Spain's IBEX 35 Index rising by 1.2%, London's FTSE 100 increasing by 1.17%, Germany's DAX 40 up by 2.62%, and France's CAC 40 adding 2.33% [6] - Asian markets also closed higher, with Japan's Nikkei gaining 1.04%, Hong Kong's Hang Seng Index surging 1.74%, and India's BSE Sensex rising by 0.32% [8]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, publications, and personal analysis intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].